<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159766">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01915394</url>
  </required_header>
  <id_info>
    <org_study_id>TurkNICU-RSV</org_study_id>
    <nct_id>NCT01915394</nct_id>
  </id_info>
  <brief_title>Management of Hospitalized Respiratory Syncytial Virus (RSV) Infected Patients in the Neonatal Intensive Care Unit (NICU) and Control of Epidemics: TurkNICU-RSV Trial</brief_title>
  <acronym>TurkNICU-RSV</acronym>
  <official_title>Management of Hospitalized Respiratory Syncytial Virus (RSV) Infected Patients in the Neonatal Intensive Care Unit (NICU) and Control of Epidemics; TurkNICU-RSV Study: A Multicentric, Prospective Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ankara University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ankara University</source>
  <oversight_info>
    <authority>Turkey: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principle purpose of this multicenter trial is to determine the definition, timing and
      the percentage of nosocomial RSV epidemics throughout Turkey. In addition, secondary purpose
      of the trial is to determine the prevention strategies of further spread of Respiratory
      Syncytial Virus (RSV) in the neonatal intensive care unit (NICU).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Hospitalized Respiratory Syncytial Virus infected Newborn in the Neonatal Intensive Care Units, and its relation with possible epidemics.</measure>
    <time_frame>Patients will be followed during hospitalization, with expected average of 3 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Patients will be followed during hospitalization, with expected average of 3 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>mortality related to RSV infection and epidemics</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Respiratory Syncytial Virus Infections</condition>
  <condition>Infections, Epidemics</condition>
  <arm_group>
    <arm_group_label>Hospitalized Respiratory Syncytial Virus Infected Newborns</arm_group_label>
    <description>All admitted newborns to the neonatal intensive care unit (NICU) will be enrolled in the study</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized RSV infected newborn infants in the NICU.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed RSV infection with either RSV-strip test or polymerase chain reaction
             (PCR).

          -  Admission to the NICU or hospitalized in the NICU between 1 October 2013 and 01 April
             2014.

        Exclusion Criteria:

          -  Refused informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omer Erdeve, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ankara University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Serdar Alan, MD</last_name>
    <phone>+905325991259</phone>
    <email>alanserdar@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Omer Erdeve, MD</last_name>
    <phone>+905054812151</phone>
    <email>omererdeve@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ankara University School of Medicine, Department of Pediatrics, Division of Neonatology</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Oncel MY, Mutlu B, Kavurt S, Baş AY, Demirel N, Akyol M, Erdeve O, Dilmen U. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey. Turk J Pediatr. 2012 Jul-Aug;54(4):344-51.</citation>
    <PMID>23692714</PMID>
  </reference>
  <reference>
    <citation>Dizdar EA, Aydemir C, Erdeve O, Sari FN, Oguz S, Uras N, Dilmen U. Respiratory syncytial virus outbreak defined by rapid screening in a neonatal intensive care unit. J Hosp Infect. 2010 Aug;75(4):292-4. doi: 10.1016/j.jhin.2010.01.013. Epub 2010 Mar 17.</citation>
    <PMID>20299133</PMID>
  </reference>
  <reference>
    <citation>Alan S, Okulu E, Kiliç A, Atasay B, Arsan S. Palivizumab use during respiratory syncytial virus outbreak in the neonatal intensive care unit. J Hosp Infect. 2012 Aug;81(4):292-3. doi: 10.1016/j.jhin.2012.05.011. Epub 2012 Jun 20.</citation>
    <PMID>22727129</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 1, 2013</lastchanged_date>
  <firstreceived_date>July 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ankara University</investigator_affiliation>
    <investigator_full_name>Serdar Alan</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Respiratory Syncytial Virus Infections</keyword>
  <keyword>Epidemics</keyword>
  <keyword>Neonatal Intensive Care Unit</keyword>
  <keyword>Newborn infants</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
